.svg){kind=small}
Nov-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Canna Clinicals has shown notable performance in the Tincture & Sublingual category within New York. Over the past few months, the brand has maintained a relatively stable position, ranking 8th in both September and October 2025, before a slight dip to 10th in November 2025. This movement indicates a competitive market where Canna Clinicals is holding its ground among the top players, although the drop in November suggests potential challenges or increased competition. The sales figures reveal a peak in October, followed by a decline in November, which might be worth investigating further to understand the underlying causes.
Outside of New York, the absence of Canna Clinicals from the top 30 brands in other states or provinces for the Tincture & Sublingual category suggests that their presence and market penetration might be limited geographically. This could represent a strategic focus on specific markets or a potential area for growth if the brand chooses to expand its reach. Understanding the dynamics in other regions could provide insights into opportunities or barriers that Canna Clinicals may face in scaling its operations beyond its current stronghold.
Competitive Landscape
In the competitive landscape of the Tincture & Sublingual category in New York, Canna Clinicals has experienced notable fluctuations in its market position over recent months. Starting from a rank of 9th in August 2025, Canna Clinicals improved to 8th place in September and maintained this position in October, before slipping back to 10th in November. This rank change reflects a dynamic market environment where competitors like Ithaca Organics Cannabis Co. have shown a consistent upward trajectory, moving from 9th in September to 7th by November. Meanwhile, Jumbodose saw a decline from 8th to 13th over the same period, indicating a potential opportunity for Canna Clinicals to capitalize on shifting consumer preferences. Despite the drop in November, Canna Clinicals' sales figures suggest a robust performance, particularly in October, which could be leveraged to regain and sustain a higher market rank amidst the competitive pressures from brands like Harney Brothers Cannabis and Chime & Chill.
Notable Products
In November 2025, Canna Clinicals' top-performing product was the CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml), maintaining its position as the number one product since August, despite a slight decrease in sales to 291 units. The CBD/THC Unwind Tincture (1050mg CBD, 90mg THC, 15ml) consistently held the second rank, showing a significant sales increase to 274 units. The CBD/CBN/THC Sleep Tincture (300mg CBD, 300mg CBN, 150mg THC) rose to third place, marking its debut in the rankings with 85 units sold. Meanwhile, the CBD/THC/CBN 1:1:1 Sleep Complex Capsules 20-Pack remained steady at fourth place, though sales dipped to 44 units. Lastly, the CBD/THC 1:1 Max Strength Capsules 10-Pack dropped to fifth place with a notable decline in sales to 20 units.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
